X4 Pharmaceuticals Inc XFOR
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-11-16 |
| Shares Out. | 94,320,000 |
| Website | x4pharma.com/ ↗ |
| Phone | 18575298300 |
| Employees | 45 |
| Revenue | $2.7M |
| Gross Profit | $2.1M |
| Net Income | -$20.2M |
| Total Assets | $270.3M |
| Total Liabilities | $101.8M |
| Equity | $168.5M |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
X4 Pharmaceuticals Inc is a publicly traded company under the ticker symbol XFOR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)